Stem Cell-Based Therapies for Lymphoma
Understanding Lymphoma and the Promise of Stem Cell Therapy Lymphoma, a type of blood cancer that affects the lymphatic system, presents a significant health challenge worldwide. It’s a complex disease with various subtypes, each requiring a unique approach to treatment. In recent years, stem cell therapy has emerged as a beacon of hope for many […]
Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]
Be The Match Foundation’s Triumph: Over $327,000 Raised at the Annual Los Angeles Soirée
In a remarkable display of philanthropy and community spirit, the Be The Match Foundation® celebrated its annual Los Angeles Soirée on August 11 at the Skirball Cultural Center. This event, dedicated to supporting patients battling life-threatening blood cancers and disorders, witnessed an astounding collection of over $327,000 in a single night. A Night of Hope […]
Autologous Stem Cell Transplant: Benefits & Risks
An autologous stem cell transplant is a medical procedure that involves taking stem cells from the body of a person, processing and storing them, and then reinfusing them back into the same person’s body. This procedure has been used to treat various kinds of illnesses, including blood cancer and other diseases of the immune system. […]
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
WEST HILLS, Calif., Jan. 24, 2023 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for IMPT-314, a bispecific “OR-Gate” autologous CAR T-cell therapy targeting the B-cell […]
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]
Allogeneic Stem Cell Transplant: Everything You Need to Know
What is allogeneic stem cell transplant? This is a question that many people are asking these days. Allogeneic stem cell transplant is a treatment option for cancer patients. It involves the infusion of healthy stem cells into the patient’s body in order to fight cancer. In this article, we will discuss all aspects of allogeneic […]